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Early experience with extended use of insulin-like growth factor-i in
advanced chronic renal failure. Short-term high-dose insulin-like growth
factor-i (IGF-1) therapy has been shown to enhance glomerular filtration
rate (GFR) in end-stage chronic renal failure (CRF), but the efficacy and
safety of prolonged therapy is unproven. To determine if prolonged
therapy with IGF-i can enhance renal function in advanced CRF, eight
patients were entered into a study to receive one month of IGF-1
treatment, 60 pg/kg subcutaneously bid. Six patients completed the study
and two dropped out for reasons considered to be unrelated to the IGF-T
treatment. Baseline inulin and PAH clearances averaged 17 3 and 66
14 ml/min/1.73 m2, respectively, in the subjects who completed the study.
With treatment there was a modest 14% increase in the average GFR
which approached statistical significance (P = 0.051). After stopping
treatment the clearance values returned to basal values. The PAH
clearance showed a similar trend. There were no significant changes in
BUN, serum creatinine or electrolyte levels. On the other hand there were
marked changes in the serum IGF binding protein (IGFBP) profile.
Serum IGFBP-3 levels fell while IGFBP-1 and -2 levels rose during
treatment, changes that likely affect the bioavailability of JGF-I. Thus, in
this small series of patients IGF-1 treatment produced significant changes
in the serum IGFBP profile and a modest upward trend in the GFR.
Chronic advanced renal failure is usually characterized by
relentless progression to end-stage renal disease. The use of
maneuvers such as dietary protein restriction, vigorous control of
blood pressure and inhibition of the angiotensin converting
enzyme may slow but will not reverse the decline in renal function
[11. Thus, an agent that actually improves renal function in
advanced chronic renal failure without accelerating progression
would be of considerable therapeutic value. Insulin-like growth
factor-i (IGF-1) is one potential agent. Administration of this
anabolic peptide growth factor to normal subjects produces an
increase in renal blood flow and glomerular filtration rate (GFR)
[21. Recently O'Shea, Miller and Hammerman [3] examined the
effect of IGF-1 in patients with moderate renal failure, and noted
an improvement in renal function and an increase in kidney size
during the four-day study period. In a more prolonged study of
patients with advanced renal failure a similar response was noted,
but the increase in GFR was not sustained beyond two weeks and
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treatment was associated with frequent and troubling adverse
effects [4]. This acquired resistance to IGF-1 and the high
incidence of side effects may have been related to the large dose
of IGF-1 used. Moreover, prolonged IGF-1 therapy may alter
IGF-1 bioavailability because of IGF-1 induced changes in the
serum IGF binding protein (IGFBP) profile.
Insulin-like growth factor binding proteins have a high affinity
for IGF-1 and readily form circulating complexes with the hor-
mone. Less than 1% of the total serum IGF-1 is in a free
bioavailable form [5, 6]. Six IGF binding proteins have been
identified and in the circulation IGFBP-3 is by far the most
abundant form. Usually —90% of the circulating IGF-1 is corn-
plexed to IGFBP-3 (— 40 to 50 kDa depending on glycosylation)
and an acid labile subunit (ALS) forming a 150 kDa moiety that
severely restricts the passage of IGF-1 from the circulation. A
small amount is bound to IGFBP -1, -2, -4 and -6 forming smaller
30 to 43 kDa complexes which are less restrictive to the transcap-
illary passage of IGF-1. The overall effect of the IGFBPs is to
prolong the serum clearance of IGF-1 [7]. Release of IGF-1 from
IGFBP complexes is achieved, in part, by circulating and tissue
proteases that lower the affinity of the IGFBP to IGF-1 [8]. In
renal failure serum IGFBP levels increase and may contribute to
the resistance to IGF-l's metabolic and growth promoting prop-
erties that develop as renal failure progresses [9, 10].
Since IGF-1 can acutely improve renal function, even in
subjects with advanced renal failure, we set out to determine
whether IGF-1, administered at a lower dose than previously
used, might produce a sustained increase in GFR in such patients
without inducing significant side effects. In addition, we examined
the effect of prolonged IGF-i treatment on the serum IGF-1
binding proteins, since the appearance of adverse effects and
refractoriness may be related to IGF-1 induced changes in these
proteins.
Methods
Subjects
Eight patients with advanced chronic renal failure, defined as
serum creatinine above 2,5 mg/dl or creatinine clearance below 30
ml/min/i.73 m2 over a period of at least three months, were
recruited for the study. Two patients who had earlier completed
an JGF-1 pharmacokinetic study in which they received a single
1GF-1 dose of 80 jtg/kg s.c. were entered into the study after a
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washout period of at least twelve weeks [7]. The key characteris-
tics of the patients are shown in Table 1. Exclusion criteria
included polycystic kidney disease, serious medical conditions
such as malignancy, chronic cardiac, liver or pulmonary disease,
collagen vascular disease, insulin requiring diabetes, malnutrition
(relative body wt < 80% or > 140% of ideal body wt, albumin <
3.3 g/dl). All patients gave their consent under a protocol ap-
proved by the Stanford University Medical Center Human Sub-
jects Review Committee.
Protocol
The study extended over six weeks and required admission to
the Aging Study Unit at the Department of Veterans Affairs Palo
Alto Health Care System on seven occasions for renal function
studies. Two weeks prior to beginning the study patients were
placed on 0.8 to 1.0 glkg protein, 3 to 4 g Na diet supplemented
with oral iron, For three days prior to and during each renal
function study the patients were given a standardized diet to
insure correct nutrient consumption. Meals were prepared and
food intake was monitored by the Study Unit nutritional staff.
Calculated protein intakes indicated compliance with the diet. At
least ten days prior to entry into the renal function study,
I-adreneric blocking agents and non-steroidal anti-inflammatory
agents were discontinued and where necessary were replaced with
agents of a different class. In addition, on the morning of each
clearance study, all antihypertensive medications were withheld
until that study was completed.
The first admission to the Study Unit was for baseline renal
function, biochemical and anthropometric measurements, Twen-
ty-four hour collections of urine were started on admission and
inulin and para-amino hippurate (PAH) clearances were mea-
sured in the mornings on the following two days. After these
baseline measurements were completed, the subjects were al-
lowed home and were then readmitted after a two to three day
period for four days of study. Recombinant human IGF-1, sup-
plied by Genentech Inc. (South San Francisco, CA, USA) was
then administered subcutaneously twice daily (7 a.m. and 7 p.m.)
at a dose of 60 j.g/kg. Subjects were taught self-administration of
Glomerular filtration rate and effective renal plasma flow
These parameters were determined from the clearances of
inulin and PAH that were measured as follows. After a light
breakfast and oral water loading, a priming infusion containing
20% PAH and 10% inulin was administered iv. and followed by
a continuous i.v. infusion of PAH and inulin to maintain a plasma
level at about 1.5 mg/dl for PAH and 20 mgldl for inulin. Urinary
losses were replaced quantitatively throughout with oral fluids.
After a 60-minute equilibration period, spontaneously voided
urine was collected half hourly for two hours. Blood was collected
at the beginning and end of each urine collection. The hematocrit
was measured on the final sample. Pulse and blood pressure were
measured at the beginning and end of each study. Inulin levels in
plasma and urine were determined enzymatically using inulinase
(Novo Nordisk Bioindustry, Danbury, CT, USA) in a two-step
colorimetric assay performed on a Cobas FARA II (Roche
Diagnostic Systems, Montclair, NJ, USA) as described by Sum-
merfield et al [11]. Serum and urinary PAH levels were measured
as previously described [12]. Clearances were calculated with
conventional formulas. The inulin and PAH clearance values were
obtained from the mean of three to four separate 30-minute
measurements per study day, while the creatinine clearances were
from single 24 hour measurements.
Biochemical parameters
Serum sodium, potassium, glucose, BUN, creatinine, urine
protein and urea nitrogen, serum and urine calcium, phosphate
were measured on a Kodak E700 autoanalyzer (Eastman Kodak,
Rochester, NY, USA). Urine sodium and potassium were mea-
sured on an IL 943 Flame Photometer (Instrumentation Labora-
tory, Lexington, MA, USA).
Anthropometrics
Arm muscle area was calculated from the midarm circumfer-
ence and triceps skin fold thickness [13]. Lean mass, fat mass, and
percent adiposity were determined by dual energy X-ray absorp-
tiometry (DEXA, Hologic, QDR 2000; Hologic Corp, Waltham,
MA, USA). Kidney volume was determined with real-time ultra-
sonographic examinations using a modified ellipsoid formula [141.
Radiolaheling of peptides
Human IGF-1, IGF-2 and non-glycosylated IGFBP-3 were
iodinated by the chloramine-T method and covalent tracers of
['251]IGF-2:IGFBP-3 was prepared and purified as described
previously [151. Recombinant IGF-2 was provided by Eli Lilly Co.
(Indianapolis, IN, USA) and non-glycosylated IGFBP-3 and
IGFBP-2 by Celtrix (Santa Clara, CA, USA). Recombinant IGF-1
was purchased from Bachem, Inc. (Torrance, CA, USA). Recom-
binant IGFBP-2 from Austral (San Ramon, CA, USA) and
Table 1. Patient characteristics at baseline
Patient Renal disease
Serum
creatinine
Age/sex mg/dl
Creatinine tnulin
clearance" clearance"
mi/mm/I. 73 m2
43/F 2.4 28 27
50/M 3.3 28 23
A FSGS'
B Interstitial
nephritis
C Bilateral small
kidneys
Chronic
pyelonephritis
D Medullaiy cystic
E IgA nephropathyaF FSGSG FSGS
H Diabetic
nephropathy
IGF-1 and educated in the recognition of the symptoms of
hypoglycemia and in its management. Renal function was moni-
tored on the second and fourth day of treatment. On completing
these measurements the patients were followed as outpatients and
were readmitted the night before the subsequent one or two day
study periods. These studies were on days 14, 30 and 31 of
treatment and again 12 to 14 days after stopping treatment.
46/F 3.8 19 14 During each admission 24-hour urine collections were made for
creatinine, urea nitrogen, protein and electrolyte measurement.
39/F
47/M
32/M
68/F
591M
5.9 12 8.0
6.5 20 12
7.0 18 17
3.7 18 15
4.1 21 17
Creatinine clearance was measured over 24 hours, inulin clearances
over 2 hours.
Abbreviation is FSGS, focal segmental glomerulosclerosis.
a Renal diagnosis proven by biopsyh Average of values measured on two sequential days
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recombinant glycosylated IGFBP-3 from Upstate Biotechnology
Inc. (Lake Placid, NY, USA).
Radioimmunoassay (RIA)
JGF-1 was measured by RIA after separation from IGFBPs by
G-50 chromatography in acid [16]. Anti-IGF-1 antiserum
(UBK487) was obtained from Drs. L.E. Underwood and J.J. Van
Wyk (Chapel Hill, NC, USA) through the National Hormone and
Pituitary Program. Serum IGFBP-3 levels were measured directly
[171 with an antiserum against IGFBP-3 provided by Dr. R.G.
Rosenfeld (University of Oregon). Covalent [1251]IGF-2:IGFBP-3
was used as the tracer for the assay. Assays for free IGF-1 were
carried out with kits provided by Diagnostics Systems Laborato-
ries, Inc. (DSL, Webster, TX, USA). The procedure employs a
two-site immunoradiometric assay principle with a minimum
detection limit of 0.05 nglml. Free IGF-1 assayed likely reflects
true free IGF-1 and IGF-1 that rapidly dissociates from IGFBPs
(presumably the low molecular weight moieties) during the assay
[18]. The interassay and intrassay coefficient of variation averages
3.6 and 5.1%, respectively. Serum IGFBP-1 levels were measured
using an immunoradiometric (IRMA) kit from Diagnostics Sys-
tems Laboratories, Inc. Samples were diluted 1:10, and assayed
according to the manufacturer's instructions. Serum IGFBP-2 was
measured in a double antibody radioimmunoassay. The antibody
against IGFBP-2 was provided by Dr. Werner Blum (TUbingen,
Germany). All samples were analyzed in the same assay.
Western ligand blotting
Serum was separated by 12% sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) under non-reducing con-
ditions. Samples were transferred onto nitrocellulose and probed
for IGFBPs with [1251J1GF-1 and -2 as described before [7].
Western immunoblots
Serum samples were separated by 12% SDS-PAGE under
non-reducing conditions and electroblotted onto nitrocellulose
[19]. Following blocking for four hours at room temperature with
0.1 M Tris-HCI, 0.15 M NaCl, and 0.1% Tween 20, pH 7.4 (TTBS)
with 2% BSA (Sigma, St. Louis, MO, USA), the blot was
incubated overnight with anti-IGFBP-3 antibody at 1:1000, or acid
labile subunit (ALS) antiserum (DSL) at 1:2000 in TTBS at 4°C.
After three washes at room temperature with TUBS, the blot was
incubated with horseradish peroxidase linked goat anti-rabbit
antibody at 1:10,000 (Amersham, Arlington Heights, IL, USA) for
60 minutes at room temperature. After three washes in TUBS, the
blot was exposed for 60 seconds to enhanced chemiluminescence
(ECL) reagents (Amersham), drained, saran wrapped, and the
antibody-labeled bands were examined by exposure to ECL
hyperfilm (Amersham) for 10 to 30 seconds.
IGFBP-3 protease assay
IGFBP-3 specific protease in serum was measured as described
[20]. Two microliters of serum were incubated with 30,000 cpm
[1251]IGFBP-3 (non-glycosylated) for four hours at 37°C, Term
pregnancy serum was used as a positive control, After separation
by 12% SDS-PAGE, intact and degraded IGFBP-3 tracer were
detected by autoradiography.
Data analysis
Data for the six patients who completed the study were subject
to analysis. Five subjects completed 31 days and one subject (A)
completed 30 days. For the purpose of analysis measurements
made on the last two days of her study are treated as day 30 and
31 values. Results are expressed as the mean SEM. Data were
analyzed for statistical significance by Student's paired I-test for
single comparisons. Repeated measures analysis of variance
(ANOVA) was used to examine the response of variables over
time. Differences were considered significant at P < 0.05. If the F
test was significant Fisher's paired least significance test was used
to make comparisons among all means.
Results
Characteristics of subjects
Eight subjects with advanced renal failure due to a variety of
diseases were recruited into the study and their characteristics are
listed in Table 1. Six subjects (A-F) completed the study. One
subject (G), a 68-year-old woman with focal glomerular sclerosis,
was removed from the study after two days of IGF-1 treatment for
reasons unrelated to the receipt of IGF-1 treatment. A second
subject (H), a 59-year-old male with diabetic nephropathy, was
discontinued after nineteen days of treatment also for reasons
considered to be unrelated to IGF-1 therapy, and this is discussed
later.
mu/in and para-aminohppurate clearance values
The effect of exogenous IGF-1 on the inulin and PAH clear-
ances in the six subjects completing the study are depicted in
Figure 1 and Table 2. Baseline inulin and PAH clearances, the
mean of measurements obtained on two consecutive days before
treatment averaged 16.7 2.9 and 66.3 14.2 ml/min/1.73 m2,
USA respectively. Following treatment there was a small and
sustained increase in the inulin clearance. The average of all the
values obtained during the treatment period, 18.9 2.9 ml/min/
1.73 m2, exceeded the baseline value by 14% but did not quite
reach significance (P = 0.051). By multiple comparison testing the
inulin clearance measured on day 4 of treatment was significantly
greater than the pre- or post-treatment values exceeding these
values by 17%. Significance was not reached on the other treat-
ment days. An increase in the average PAH clearance of 18% was
also noted but this was not statistically significant. After discon-
tinuing IGF-1 treatment the inulin and PAH clearances returned
to basal values.
Serum and urine hiochemistiy
The results of serum and urine measurements are listed in
Tables 3 and 4, respectively. There was no significant difference in
any of the serum biochemical parameters measured during the
study. However, the average BUN levels were lower during the
IGF-1 treatment period (39 9 mg/dl on day 31) when compared
to the pre-treatment and post-treatment values (52 10 and 57
12 mgldl). A similar trend was noted with the serum glucose
levels, which at its lowest (84 3.2 mg/dl) remained within the
normal range. Serum creatinine levels were also lower at the end
of the treatment period compared to the pretreatment value
(4.1 0.1 vs. 4.8 0.8 mg/dl). Urinary parameters, including
protein excretion, did not change significantly during IGF-1
treatment (Table 4). However, the maximum percent tubular
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Fig. 1. Effect of IGF-J treatment on the (A) mu/in and (B) PAH clearances.
The values shown on day —4 (pretreatment) and on day 30 are the average
of measurements obtained on two consecutive days. Data are expressed as
a percent of the mean pretreatment baseline values which was assigned a
value of 100. Results are mean SEM from 6 subjects. *p < 0.05 versus
pre- and post-treatment values.
reabsorption of phosphate was on average higher during treat-
ment reaching a maximum of 59 8% on day 31 compared to the
basal value of 47 7%. The fractional excretion of filtered
sodium fell from an average pretreatment value of 3.6 0.8% to
a low of 1.9 0.45% when treatment was initiated hut then rose
with time to as high as 4.2 0.6%. The increase likely reflects the
institution of diuretics. Urinary nitrogen excretion values were on
average lower during treatment and together with the fall in BUN
levels in these subjects on a constant diet suggest that IGF-1 may
have a positive effect on nitrogen balance. Subjectively all the
patients reported that they experienced a boost in energy and an
improved sense of well being.
Hemodynamic parameters
These are shown in Table 5. During the treatment period the
average pulse rate increased to a maximum of 26% over the basal
rate. This increase did not reach statistical significance. Blood
pressure was essentially unchanged.
Anthropometrics
Listed in Table 6 are anthropometric measurements obtained
before and after treatment with IGF-1. There was no significant
change in any of the parameters measured. Kidney volume (N =
4) was unchanged by IGF-1 treatment and averaged 139 26 cm3
before and 135 28 cm3 after the end of treatment.
Serum IGF-I, IGF binding proteins and acid labile subunit
Serum total and free IGF-1 levels were elevated several fold
above the basal values during IGF-1 treatment (Fig. 2). Immuno-
reactive IGFBP-1 and -2 levels rose more than two- and more
than threefold, respectively, while immunoreactive IGFBP-3 lev-
els fell by one third (Fig. 3). After discontinuing treatment all
these parameters returned to basal values. Western ligand blot
analysis, which relies on the ability of the IGFBP to bind
radioligand, showed a treatment induced increase in the —34 kDs
band that is the size of IGFBP-2 (Fig. 4A), The diffuse signal seen
between the 26 to 30 kDa region of the gel probably represents
fragmented or deglycosylated IGFBPs. The most conspicuous
signal, a 38 to 42 kDa doublet the size of IGFBP-3 was essentially
unchanged throughout the course of treatment. Western immu-
noblots with an antibody against IGFBP-3 confirmed that the 38
to 42 kDa doublet is in fact immunoreactive IGFBP-3 and that it
was unaffected by treatment (Fig. 4B). The antibody also detected
a 29 kDa protein that presumably represents an IGFBP-3 cleav-
age product. With treatment the concentration of this protein
decreased and likely accounts for the fall in immunoreactive
IGFBP-3 levels. Interestingly, the activity of the IGFBP-3 pro-
tease was unaffected by IGF-1 treatment (Fig. 5). Western
immunoblots performed to measure ALS showed no change
following IGF-1 administration (Fig. 6).
Adverse reactions
The adverse events encountered during the period of IGF-1
therapy are listed in Table 7 and include all eight subjects initially
enrolled into the study. Four patients tolerated the treatment very
well. Three patients complained of symptoms referable to fluid
retention and this was treated with diuretics. In one subject (D)
this worsened following an increase in the IGF-1 dose to 80 j.rg/kg
bid, after fourteen days of treatment. The dose was reduced to 70
kg/kg b.i.d. and her diuretic dose was increased. Mild headaches
were experienced by two patients which resolved with reduction in
the IGF-1 dose. One patient (A) developed a local hypersensitiv-
ity reaction at the injection site of IGF-i. This improved but did
not resolve following a dose reduction to 45 .tg/kg h.i.d. anti a
change in formulation of the vehicle. Treatment was limited to 30
days in this patient. One patient (G) experienced atypical chest
pain without EKG or enzyme changes after two days of receiving
IGF-1 and was discontinued from the study. Similar episodes
recurred when not receiving IGF-I. Another patient (H), a
59-year-old diabetic with nephropathy and a history of hyperten-
sion, congestive cardiac failure and bronchial asthma, developed
increasing fluid retention prompting an increase in diuretics.
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Table 2. Effect of IGF-I on renal function
Period of IGF-I treatment
Parameter Pre Day 2 Day 4 Day 14 Day 30 Day 31 Post
Inulin clearance 16.7 2.9 18.6 3.1 19.6 3.6" 18.1 2.5 19.2 3 19.2 2.8 15.9 2.1
mI/mm/i. 73 m2
PAH clearance 66.3 14.2 75.4 18.1 80.1 17.7 83.6 18.0 72.7 17.1 79.5 18.3 64.6 12.5
ml/min/1.73 m2
Filtration fraction 28.7 5.6 29.2 6.0 28.0 5.9 25.4 5.4 33.2 6.9 29.3 6.6 29.6 7.2
Values are expressed as mean SEM.
"P < 0.05 vs. pretreatment values
Table 3. Effect of IGF-1 on serum values
Period of IGF-I treatment
Parameter Pre Day 2 Day 4 Day 14 Day 30 Day 31 Post
BUN mg/di 52 10 47 9 44 9 42 10 43.2 10 39.2 9 57 12
Creatinine mg/dl 4.8 0.8 4.9 0.9 4.6 0.7 4.4 0.6 4.9 0.1 4.1 0.1 4.9 0.7
Na mEq/iiter 140 0.8 141 1.1 139 0.5 141 1.2 141 1.1 141 1.1 141 1.5
K mEq/liter 4.2 0.1 4.4 0.1 4.2 0.2 4.5 0.1 4.7 0.1 4.6 0.1 4.5 0.2
Chloride mEq/liter 106 2.7 105 1.5 105 1.1 107 1.9 108 1.3 107 1.7 107 2.5
Glucose mg/dl 94 3.9 89 3.6 90 1.9 84 3.2 84 1.5 85.6 1.5 93 3.7
Albumin g/di 4.0 0.1 3.7 0.1 3.85 0.1 4.17 0.15
HCO3 mEq/iiter 25 1.0 25 1.6 24 0.9 23 1.8 24 1.3 24.5 1.1 25 1.3
Calcium mg/dl 9.0 0.1 9.1 0.2 8.9 0.2 8.9 0.2 9.2 0.2 9.1 0.2 9.2 0.2
Phosphate mg/dl 3.7 0.3 3.7 0.2 3.6 0.2 3.9 0.4 3.9 0.3 4.2 0.4 4.3 0.2
Cholesterol mg/dl 189 15 191 15 177 13 190 9 190 9 189 10 210 8
Values are expressed as means SEM.
Table 4. Effect of IGF-I on urinaly values
Period of IGF-1 treatment
Parameter Pre Day 2 Day 4 Day 14 Day 30 Day 31 Post
Volume mi/day 2407 230 1983 237 1692 180 1985 141 2073 135 2617 303 1443 242
Creatinine mg/day 1443 226 1531 324 1470 284 1576 281 1553 247 1451 244 1443 242
Protein g/day 1.9 0.41 1.8 0.47 1.9 0.68 2.5 0.68 1.8 0.43 1.7 0.45 1.6 0.39
UUNg/day 7.02 0.6 6.63 0.65 6.22 0.7 5.98 0.6 6.95 0.7 6.51 0.45 7.43 0.8
ERp.Eq/min 26±4 25±3 24±4 26±2 33±3 27±2 30±4
ER.jig/min 24±6 19±5 18±6 29±7 31±12 34±13 26±9
ERNjLEq/min 68±10 44±4 37±5 77±11 80±9 90±9 82±4
ER p.g/min 370 30 330 50 300 50 320 50 360 50 360 50 410 50
TR pg/mm 47 7.1 53 8.0 54 8.5 58 7.2 57 7.2 59 8.0 49 7.1
TRK % 64 7.4 69 5.1 71 5.2 71 8.1 68 7.6 73 5.2 60 7.0
FEN. 3.6 0.83 1.9 0.45 1.9 0.47 3.7 0.75 3.3 0.79 4.2 0.63 4 0.86
Values are expressed as means SEM.
Abbreviations are: ER, excretion rate; TR, tubular reabsorption; FE, fractional excretion.
After two weeks of IGF-1 his inulin clearance was unchanged
from the basal value (17 ml/min/1.73 m2). Four days later he was
admitted to an outside facility with chest pain and shortness of
breath and fluid overload. Following a blood transfusion for
anemia he developed pulmonary edema, and as his serum creat-
mine level had risen from 4.1 to 7.0 mg/dl he was hemodialyzed.
A diagnosis of myocardial infarction and end-stage renal disease
was made and he was maintained on regular dialysis therapy. Five
weeks later because of vascular access clotting, dialysis was
withheld and at this time it was apparent that the patient had
recovered baseline renal function, serum creatinine 4.3 mg/dl.
Over the ensuing 17 months dialysis was not required, though
there were transient prerenal increases in the serum creatinine
levels that stabilized at 6.5 mgldl during the last four months of
follow-up. While we are not sure of the cause of the acute renal
failure, this episode is consistent with prerenal failure secondary
to cardiac decompensation following a myocardial infarct. The
Table 5. Effect of IGF-I on hemodynamics and other values
Period of IGF-1 treatment
Parameter Pre Day 2 Day 4 Day 14 Day 30 Post
SBPmmHg 124±4 126±5 125±6 127±6 133±7 122±6
DBPmmIIg 78±4 78±4 80±4 82±4 81±4 76±4
Pulserate 72±5 82±6 91±5 89±6 83±4 73±4
MABP 93±4 90±3 91±3 97±5 96±5 91±4
Valucs are expressed as means SEM.
Abbreviations are: SBP, systolic blood pressure; DBP, diastolic blood
pressure; MABP, mean arterial blood pressure.
latter was considered to be unrelated to the IGF-1 therapy since
this subject had several high risk factors that predisposed to such
a cardiac event. In this regard there are, to our knowledge, no data
at present to suggest that there is an increased risk of myocardial
infarction in IGF-1 treated subjects.
Values are means SEM.
Abbreviations are: BMD, bone mineral density;
content; AMA, arm muscle area.
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Table 6. Effect of IGF-I on anthropometrics
Parameter N patients Pre Treatment
Body weight kg
BMD g/cm3 4
74 4,5
1.09 0.06
74 4.3
1.09 0.05
BMCg 4 25.3 0.29 25.2 0.31
Fat mass kg 4 17.9 2.1 17.1 2.0
Lean mass kg 4 52.9 7.4 59.4 7.5
Adiposity % 4 25.0 4.0 24.0 4.0
AMA cm2 6 43.7 6.6 45.2 6.1
A
300
250
200
150LJ0
A —5 0 5 10 15 20 25 30 35 40 45 50
B
BMC, bone mineral 100
50
10000
8000
6000
c'S
4000U-
2000
0
Time, days
—5 0 5 10 15 20 25 30 35 40 45 50
Time, days
B
—5 0 5 101520253035404550
Time, days
C
7000
6000
800
700
600
-
500
400
L0 300
200
100
0
10
9
8
6
C!:,
-; 4
ci)
U- 3
2
0
—5 0 5 10 15 20 25 30 35 40 45 50
Time, days
Fig. 2. Serum immunoreactive (A) total IGF-J and (B) free IGF-1 levels
bejbre, during and after treatment with IGF-1 (N = 6).
Long-term renal follow-up
This was evaluated by the serum creatinine level and need for
dialysis. The three subjects with the highest serum creatine levels
on entry into the study (subjects D, E and F, Table 1) reached
5000
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Time, days
Fig. 3. Serum immunoreactive IGF13P-1 (AZ), -2 (B) and -3 (C) levels
before, during and after treatment with IGF- 1. N = 6.
end-stage renal failure and were placed on maintenance dialysis
ten to twelve months after completing their course of IGF-I
therapy. In contrast, the serum creatinine levels in the subjects
with the lowest entry levels (subjects A and B) were essentially
unchanged over a twelve month period. In two other subjects the
serum creatinine rose over time. In subject C the serum creatinine
level rose from a baseline of 3.8 mg/dl and after twelve months
was 5.6 mgldl. In the subject withdrawn from the study after
nineteen days of IGF-I treatment the serum creatinine rose from
the basal level of 4.1 mg/dI, and after seventeen months the steady
state level was 6.5 mg!dl. Taken together, these course of events
are consistent with the natural history of the underlying kidney
sees —Se
pre 4 14 30 post pre 4 14 30 post
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28 — Fig. 6. Western immunoblots of serum acid-labile subunit (ALS). Samples
were obtained before, during (days 4, 14 and 30) and after treatment with
IGF-1.
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Fig. 4. A. Western ligand blot of serum IGFBI-'s before, during (days 4, 14
and 30) and after treatment with IGF-1. B. Western immunoblot with
antibody against IGFBP-3.
diseases. Thus, treatment with TGF-I does not appear to have
long-term adverse effects on renal function.
Discussion
Administration of recombinant human lOF-1 to normal adults
is followed by marked changes in renal function [21. These include
an increase in GFR and RPF of 22% and 32%, respectively, and
a fall in tubular phosphate excretion. In euvolemic subjects
sodium reabsorption may be increased. When given to subjects
suffering from a variety of catabolic states including end-stage
renal disease requiring dialysis, IGF-1 induces positive nitrogen
Subject Event Treatment Outcome
A Mild fluid retention
Headache
Diuretic
IGF-l dose
decreased
Resolved
Resolved
Palpitations
Delayed hypersensitivity Vehicle
formulation
changed
Improved
B None — —
C None — —
D" Mild fluid retention
Headache
Diuretic increased
IGF-I dose decreased
Resolved
Resolved
E None — —
F None — —
G5 Atypical chest pain IGF-J discontinued Recurrent
atypical
chest pain
H" Fluid retention
Myocardial infarct
with
secondary acute
renal failure
Diuretic increased
IGF-I discontinued
Retention
persisted
Resolved
Hemodialysis Resolved
balance [21, 22j. With all these salutary actions in mind we
administered IGF-1 to subjects with advanced CRF for a period of
one month. This treatment produced a threefold increase in total
serum IGF-1 levels accompanied by an even greater increase in
free IOF-l levels. Over the period of treatment there was a
modest 14% increase in the average inulin clearance, an incre-
ment that reached near statistical significance (P 0.051). The
maximum increase in GFR on any one day was on the fourth
treatment day and exceeded both the control and post-treatment
value by 17%; this was significant by multiple comparison testing
and is consistent with previous studies [4, 5J. After stopping
treatment the clearance values returned to the pretreatment
values. The PAH clearance showed a similar trend and the
average clearance during treatment exceeded the pretreatment
value by 18%.
There were no significant changes in the serum chemistries or
urinary excretion of phosphate, electrolytes, protein or urea
nitrogen. There were, however, trends that are worth noting. The
BUN levels fell from an average of 52 to a low of 39 mg/dl while
41 —
38 — Day pre 4 14 30 post pre 4 14 30 post
II
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38 —
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Day pre
Table 7. Adverse events encountered during study
ubject t 
4 14 30 post
kDa
29 —
20 —
16—
Day L_J L_JV2 141
Tracer Preg Subject A370
1—2 141L._J
Subject D Tracer
40
Subjects were treated with 60 jig/kg IOF-t s.c. B.I.D.
a Headache followed an increase in IGF-I to 80 jig/kg and resolved
when placed on 70 jig/kg
hApparently unrelated to IGF-I therapy
° Myocardial infarction with secondary acute renal failure was consid-
ered to be unrelated to IGF-I therapy
Fig. 5. Effect of IGF-1 treatment on serum IGFBP-3 protease activity.
Pregnancy serum and serum from CRF subjects before, during (day 4, 14
and 30) and alter IGF-1 treatment were incubated at 37°C with recombi-
nant '25t-IOFBP-3. For comparison tracer alune was incubated at 37°C or
4°C. Protcasc activity was unaffected by IGF-I therapy.
s a a a a
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urinary urea nitrogen also decreased, suggesting a positive effect
on nitrogen balance. Fractional phosphate reabsorption increased
from 47 to 59% but was not associated with increased serum
phosphate levels. Fractional excretion of filtered sodium fell from
3.6 to 1.9% on IGF-1 treatment, but increased to 4.2% when
diuretics were instituted or increased because of fluid retention.
Apart from the modest effect on nitrogen balance noted above,
IGF-1 treatment did not have any measurable effect on nutritional
state or body composition. Since these subjects were in a good
nutritional state on entry to the study and as the anabolic actions
of IGF-1 are most apparent in catabolic states [221, this negative
finding should not be extrapolated to patients with renal failure
who are malnourished and catabolic.
An earlier report of four CRF subjects with GFR ranging
between 22 and 55 ml/min who received higher doses of IGF-1
(100 g!kg b.i.d.) for four days described a significant increase in
the inulin clearance which averaged 36 to 40% above basal values
[3]. In subjects with more severe functional impairment these
same investigators observed a smaller (23%) increment in inulin
clearance during a similar treatment period [4]. This increase is
comparable to that described in euvolemic normal subjects [2] and
indicates that in these CRF subjects renal responsiveness to high
dose IGF-1 was retained. There have been other attempts to
augment chronically impaired renal function by administering
hormones that increase renal function in normal subjects. These
include growth hormone and atrial natriuretic peptide. Despite
improving body growth in children with CRF, GH does not
increase the GFR in these children or in adults with CRF [23, 24].
Meyer-Lehnert et al [25] reported that atrial natriuretic peptide
increased GFR significantly during a 60-minute i.v. infusion
period in a group of eight subjects with baseline inulin clearances
of 18 to 80 mI/mm/I .73 m. However, it was not apparent whether
the subjects with the lowest GFR values responded. In contrast,
Windus et al [261 studying sixteen CRF subjects with GFRs
ranging from 9 to 61 mi/mm, found that atrial natriuretic peptide
had no effect on GFR or RPF, though sodium excretion did
increase.
Because of the association between hyperfiltration and progres-
sive renal damage [1], and as IGF-1 can stimulate production of
extracellular matrix components in cultured mesangial cells [27], it
has to be considered whether IGF-1 therapy could accelerate the
natural decline in renal function of patients with CRF. Such an
event was not witnessed in the present study of one month of
IGF-1 treatment. Nevertheless, the potential for this side effect
cannot be excluded from currently available data. Thus, careful
monitoring of patients with impaired renal function who are
receiving long-term IGF-i therapy is needed. On the other hand,
studies of the prolonged USC of GH on children with CRF in order
to promote growth argues against IGF-1 induced acceleration of
progressive renal failure [24]. In these children serum IGF-1 levels
are increased three- to fourfold without adverse renal affects.
Also, there is no evidence that acromegalics who have sustained
elevations of IGF-1 and of GFR and renal blood flow for several
years are at risk of renal damage [281. Animal studies also indicate
that chronic elevations of serum IGF-1 levels do not harm the
kidney. For example, mice transgenic for IGF-1 while developing
glomerular hypertrophy, do not develop glomerulosclerosis [29]
as occurs in GH transgenics. Furthermore, while long-term GH
treatment of rats with puromycin induced glomerulosclerosis
accelerates kidney damage [30], IGF-1 treatment does not [31].
Taken together, this suggests that in animals GH may mediate
renal damage through an IGF-1 independent mechanism. One
explanation for the lack of acceleration of existing kidney disease
by IGF-1 may be in the observation of Hirschberg and Kopple [32]
that in rats IGF-1 increases GFR without increasing glomerular
capillary pressure.
In a companion study that included two of the present subjects,
we noted several changes in the serum IGFBP profile of patients
with CRF when compared to normals [7]. Among these changes
were an increase in serum IGFBP-1 and -2 levels. Serum levels of
immunoreactive ALS, a glycoprotein that forms a 150 kDa
complex with circulating IGF-1 and IGFBP-3, was unaffected.
Immunoreactive IGFBP-3 levels were also elevated. Western
immunoblots revealed that this was due to an increase in the level
of 29 kDa fragments derived from the intact IGFBP-3 moiety that
was present in normal levels. Since IGFBP-3 protease activity was
normal, it appears that the fragment accumulation is due to
reduced elimination. In the present study immunoreactive IG-
FBP-3 levels fell during the period of IGF-1 treatment. This
response is consistent with previous reports [4, 33]. However, by
Western immunoblot analysis we determined that this decline was
solely due to a fall in the level of the immunoreactive 29 kDa
fragments; intact 38 to 42 kDa IGFBP-3 levels were essentially
unchanged. Since the 29 kDa IGFBP-3 fragment binds poorly to
IGF-1, reflected by the difficulty in detection by Western ligand
blotting (Fig. 6), it is unlikely that the IGF-1 induced fall in this
serum fragment level would impact on the bioavailability of the
hormone. To explain the fall in the 29 kDa fragment we consid-
ered the possibility that the IGF-1 induced fall in IGFBP-3
fragments might be due to attenuated protease activity but found
that IGFBP-3 protease activity was unaffected by treatment.
Whether this change in fragment level reflects a decrease in
production or an increase in clearance still remains to be eluci-
dated.
In contrast to the fall in total immunoreactive IGFBP-3 in
serum, the levels of immunoreactive IGFBP-1 and -2 levels rose
two- to threefold with treatment. Similar findings have been
observed following IGF-1 treatment of type II diabetics and
calorie restricted subjects [33, 34]. Because of their high affinity
for IGF-i this increase in low molecular weight IGFBPs may well
effect the bioavaiiability of IGF-1. When bound to IGFBP-1 and
-2 (molecular wts 30 and 34 kDa, respectively) IGF-1 moves out of
the circulation more rapidly than IGF-1 bound to the 150 kDa
IGFBP-3-ALS complex. However, compared to free IGF-1 its
movement is restricted [5, 6]. Thus, the likely overall effect of
elevated serum low molecular weight IGFBPs in the presence of
normal IGFBP-3 and ALS levels will be to attenuate the bioavail-
ability of the recombinant IGF-1 [5, 6]. This in turn may contrib-
ute to the acquired resistance to IGF-l that may accompany
high-dose IGF-I treatment [4, 33]. Accordingly, when planning
long-term IGF-1 administration these changes in IGFBP levels
must be considered.
Insulin-like growth factor-i when administered in high dose
may induce certain well-recognized adverse effects. These include
hypoglycemia, tachycardia, fluid retention, Bells palsy and benign
intracranial hypertension [4, 34, 35]. Indeed, because of side
effects and acquired resistance to IGF-I the initial benefits of
IGF-1 treatment were largely negated in an earlier report of the
use of IGF-i in advanced CRF [4]. In this study we used a
relatively modest dosage regimen that included a dose reduction
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at the earliest appearance of a side effect or in the event of fluid
retention additional diuretic therapy. Accordingly, adverse effects
were mild and of short duration. Indeed, the patients reported an
overall sense of well being while on treatment. Whether this was
a real or placebo effect could not be ascertained because of the
design of the study. In three patients significant fluid retention
developed and diuretics were prescribed. In one of these subjects,
a 59-year-old diabetic with a prior history of hypertension and
congestive cardiac failure, fluid retention and renal function
worsened after a myocardial infarct necessitating temporary he-
modialysis. Seventeen months later this patient remained off
dialysis despite transient episodes of renal decompensation. The
cardiac event was considered to be unrelated to the IGF-1
administration in this patient with several high risk factors that
predispose to such an event.
In summary, we have shown that prolonged administration of
IGF-1 to subjects with advanced CRF improves the creatinine
clearance modestly and produces a small upward trend in the
inulin clearance and in nitrogen balance. This was associated with
easily manageable side effects. Taken together, these findings
support the need for more extensive studies in a larger number of
subjects in which the dose response to IGF-l is examined. Since
combined GH and IGF-1 therapy is more potently anabolic than
IGF-1 alone both in uremic rats 36] and caloric restricted humans
[22, 33], a strong case can be made for pursuing studies in which
combined IGF-1 and GH treatment are employed. In this study,
IGF-1 treatment induced major changes in the serum IGFBP
profile that will likely impact on the bioavailability of IGF-1 and
serves as an alert that long courses of IGF-1 therapy will require
dosage modification over time. This is of course also relevant to
other circumstances in which IGF-1 may be used in CRF, such as
to improve nutrition and perhaps to promote growth [21, 311.
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